SCHEMBL7185547

SCHEMBL7185547

COc1ccc(C(=O)P(=O)(C(=O)c2c(C)cc(C(C)(C)C)cc2C)c2ccccc2)c(OC)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 4/20 0.46
RAB9A P51151 3/20 0.46
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
MAPT P10636 5/20 0.45
ALDH1A1 P00352 4/20 0.41
HTT P42858 2/20 0.41
HPGD P15428 2/20 0.41
GAA P10253 1/20 0.41
PKM P14618 1/20 0.41
AKR1C3 P42330 1/20 0.41
AKR1C2 P52895 1/20 0.41
LMNA P02545 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
NR1H4 Q96RI1 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
ABCG2 Q9UNQ0 4/20 0.39
POLB P06746 1/20 0.39
TNFRSF1A P19438 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7175676 0.90 NPC1 (0.48) NPC1RAB9AMEN1KMT2AMAPT
SCHEMBL7188247 0.89 MAPT (0.51) NPC1RAB9AMEN1KMT2AMAPT
SCHEMBL7178020 0.89 KMT2A (0.39) NPC1RAB9AMEN1KMT2AMAPT
SCHEMBL28604964 0.86 NPC1 (0.58) NPC1RAB9AMEN1KMT2AMAPT
SCHEMBL7180979 0.86 NPC1 (0.46) NPC1RAB9AMEN1KMT2AMAPT
SCHEMBL7187909 0.85 NPC1 (0.52) NPC1RAB9AMEN1KMT2AMAPT
SCHEMBL7177176 0.84 NPC1 (0.51) NPC1RAB9AMEN1KMT2AMAPT
SCHEMBL7184400 0.84 CA12 (0.42) NPC1RAB9AKMT2AMAPTALDH1A1
SCHEMBL7190322 0.83 NR1H4 (0.37) MEN1KMT2AMAPTALDH1A1HTT
SCHEMBL7187514 0.82 LMNA (0.40) RAB9AMEN1KMT2AMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 NPC1 772/4885RAB9A 1818/4885MEN1 2312/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 NPC1 872/4885RAB9A 2155/4885MEN1 2263/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.